Richer, Amanda L <br/><br/>
WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.  [electronic resource] 

 -  Cancer research  09 2017 
 - 4663-4672 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1538-7445 
<br/><br/><label>Standard No.: </label>10.1158/0008-5472.CAN-16-3565  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>AMP-Activated Protein Kinases<br/>Animals<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cell Cycle Checkpoints--drug effects<br/>Cell Cycle Proteins--antagonists & inhibitors<br/>Cell Survival--drug effects<br/>Drug Evaluation, Preclinical<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Mice<br/>Mice, Transgenic<br/>Mutation--genetics<br/>Nuclear Proteins--antagonists & inhibitors<br/>Phosphorylation--drug effects<br/>Protein Serine-Threonine Kinases--deficiency<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Proto-Oncogene Proteins p21(ras)--genetics<br/>Pyrazoles--pharmacology<br/>Pyrimidines--pharmacology<br/>Pyrimidinones<br/>Tumor Cells, Cultured